About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Pulmonary Pharmacology and Therapeutics
›
top-articles
Pulmonary Pharmacology and Therapeutics
2.7
(top 20%)
impact factor
1.9K
(top 10%)
papers
46.0K
(top 10%)
citations
81
(top 10%)
h
-index
2.8
(top 20%)
impact factor
2.2K
all documents
47.9K
doc citations
109
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review
Pulmonary Pharmacology and Therapeutics
2007
273
2
Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway
Pulmonary Pharmacology and Therapeutics
2008
272
3
The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
Pulmonary Pharmacology and Therapeutics
2010
270
4
Reactive Oxygen Species as Mediators in Asthma
Pulmonary Pharmacology and Therapeutics
2001
260
5
The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
Pulmonary Pharmacology and Therapeutics
2010
233
6
Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes
Pulmonary Pharmacology and Therapeutics
2004
200
7
Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.
Pulmonary Pharmacology and Therapeutics
2014
179
8
cAMP regulation of airway smooth muscle function
Pulmonary Pharmacology and Therapeutics
2013
177
9
Epidemiology of Cough
Pulmonary Pharmacology and Therapeutics
2002
167
10
The Non-neuronal Cholinergic System: an Emerging Drug Target in the Airways
Pulmonary Pharmacology and Therapeutics
2001
162
11
Clinical Application of Forced Oscillation
Pulmonary Pharmacology and Therapeutics
2001
160
12
Relationship between neutrophil elastase and acute lung injury in humans
Pulmonary Pharmacology and Therapeutics
2004
158
13
Resolvin D1 protects mice from LPS-induced acute lung injury
Pulmonary Pharmacology and Therapeutics
2011
157
14
ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic
Pulmonary Pharmacology and Therapeutics
1999
156
15
Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2–Keap1 signaling
Pulmonary Pharmacology and Therapeutics
2009
153
16
Glucocorticoid-regulated Transcription Factors
Pulmonary Pharmacology and Therapeutics
2001
149
17
Chronic ‘cough hypersensitivity syndrome’: A more precise label for chronic cough
Pulmonary Pharmacology and Therapeutics
2011
149
18
The Powerful Placebo in Cough Studies?
Pulmonary Pharmacology and Therapeutics
2002
143
19
Exploring lung physiology in health and disease with lung slices
Pulmonary Pharmacology and Therapeutics
2011
143
20
Molecular Mechanisms of Glucocorticosteroid Actions
Pulmonary Pharmacology and Therapeutics
2000
141
21
The inhalers of the future? A review of dry powder devices on the market today
Pulmonary Pharmacology and Therapeutics
2003
136
22
Lung cancer in patients with idiopathic pulmonary fibrosis
Pulmonary Pharmacology and Therapeutics
2017
129
23
Bleomycin lung toxicity: who are the patients with increased risk?
Pulmonary Pharmacology and Therapeutics
2005
128
24
Transforming growth factor-β and its role in asthma
Pulmonary Pharmacology and Therapeutics
2003
127
25
Markers of disease severity in chronic obstructive pulmonary disease
Pulmonary Pharmacology and Therapeutics
2006
127
26
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
Pulmonary Pharmacology and Therapeutics
2004
126
27
Platinum nanoparticle antioxidants inhibit pulmonary inflammation in mice exposed to cigarette smoke
Pulmonary Pharmacology and Therapeutics
2009
126
28
Review of the Molecular and Cellular Mechanisms of Action of Glucocorticoids for Use in Asthma
Pulmonary Pharmacology and Therapeutics
2002
125
29
Calcitonin gene-related peptide as inflammatory mediator
Pulmonary Pharmacology and Therapeutics
2003
125
30
The airway cholinergic system: physiology and pharmacology
Pulmonary Pharmacology and Therapeutics
2004
124
31
Production of reflex cough by brainstem respiratory networks
Pulmonary Pharmacology and Therapeutics
2004
122
32
The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study
Pulmonary Pharmacology and Therapeutics
2008
121
33
Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach
Pulmonary Pharmacology and Therapeutics
2015
118
34
One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium
Pulmonary Pharmacology and Therapeutics
2005
112
35
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Pulmonary Pharmacology and Therapeutics
2016
112
36
Resveratrol alleviates bleomycin-induced lung injury in rats
Pulmonary Pharmacology and Therapeutics
2007
111
37
Effect of inhaled corticosteroids on small airways in asthma: Investigation using impulse oscillometry
Pulmonary Pharmacology and Therapeutics
2009
111
38
Protease-activated Receptor-2 (PAR2) in the Airways
Pulmonary Pharmacology and Therapeutics
2001
110
39
Alternative mechanisms for tiotropium
Pulmonary Pharmacology and Therapeutics
2009
109
40
TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water
Pulmonary Pharmacology and Therapeutics
2010
108
41
Physiology and Plasticity of Putative Cough Fibres in the Guinea Pig
Pulmonary Pharmacology and Therapeutics
2002
106
42
Onset of Bronchodilation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single Inhalers
Pulmonary Pharmacology and Therapeutics
2001
105
43
Emerging roles for cholesterol and lipoproteins in lung disease
Pulmonary Pharmacology and Therapeutics
2013
105
44
Short- and long-term reproducibility of capsaicin cough challenge testing
Pulmonary Pharmacology and Therapeutics
2003
104
45
Leukotrienes as Mediators of Asthma
Pulmonary Pharmacology and Therapeutics
2001
102
46
Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients
Pulmonary Pharmacology and Therapeutics
2005
102
47
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
Pulmonary Pharmacology and Therapeutics
2010
102
48
Sulfur mustard-induced pulmonary injury: Therapeutic approaches to mitigating toxicity
Pulmonary Pharmacology and Therapeutics
2011
102
49
Statins, systemic inflammation and risk of death in COPD: The Rotterdam study
Pulmonary Pharmacology and Therapeutics
2013
102
50
Complex phenotypes in asthma: Current definitions
Pulmonary Pharmacology and Therapeutics
2013
102
site/software ©
exaly
; All materials licenced under
CC by-SA
.